Cargando…

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua

BACKGROUND: Limited information exists regarding the factor IX (FIX) coagulant activity (FIX:C) measured by different assays following FIX‐Padua gene therapy. OBJECTIVE: Assess for the first time FIX:C in five commonly used coagulation assays in plasma samples from hemophilia B subjects receiving FI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robinson, Mary M., George, Lindsey A., Carr, Marcus E., Samelson‐Jones, Benjamin J., Arruda, Valder R., Murphy, John E., Rybin, Denis, Rupon, Jeremy, High, Katherine A., Tiefenbacher, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	HAEMOSTASIS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130854/ https://www.ncbi.nlm.nih.gov/pubmed/33636038 http://dx.doi.org/10.1111/jth.15281

Ejemplares similares

Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity
por: Lombardi, Silvia, et al.
Publicado: (2021)

Probing activation‐driven changes in coagulation factor IX by mass spectrometry
por: Freato, Nadia, et al.
Publicado: (2021)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Performance of factor IX extended half‐life product measurements in external quality control assessment programs
por: Nederlof, Angelique, et al.
Publicado: (2020)

Hydrogen‐deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
por: Bar Barroeta, Awital, et al.
Publicado: (2019)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs
por: Spronck, Elisabeth A., et al.
Publicado: (2019)

Underestimation of N‐glycoPEGylated factor IX one‐stage clotting activity owing to contact activator‐impaired activation
por: Persson, Egon, et al.
Publicado: (2017)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua
por: Weber, Alfred, et al.
Publicado: (2018)

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa
por: Yi, B. Alexander, et al.
Publicado: (2021)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Extracellular vesicles from amniotic fluid, milk, saliva, and urine expose complexes of tissue factor and activated factor VII
por: Hu, Yong, et al.
Publicado: (2022)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
por: Valke, Lars L.F.G., et al.
Publicado: (2020)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Comparative sequence analysis of vitamin K‐dependent coagulation factors
por: Stojanovski, Bosko M., et al.
Publicado: (2022)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
por: Haurigot, Virginia, et al.
Publicado: (2010)

Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding
por: Atiq, Ferdows, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Characterization of laboratory coagulation parameters and risk factors for intraventricular hemorrhage in extremely premature neonates
por: Roberts, Jonathan C., et al.
Publicado: (2022)

Reproductive health and hemostatic issues in women and girls with congenital factor VII deficiency: A systematic review
por: Abdul‐Kadir, Rezan, et al.
Publicado: (2022)

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa
por: Thomas, Dirk, et al.
Publicado: (2021)

Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach
por: Winterling, Karina, et al.
Publicado: (2021)

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts
por: Chun, Haarin, et al.
Publicado: (2022)

Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and non‐genetic factors
por: Temba, Godfrey S., et al.
Publicado: (2022)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
por: Pagliari, Maria Teresa, et al.
Publicado: (2022)

FVIII inhibitors display FV‐neutralizing activity in the prothrombin time assay
por: Arsiccio, Andrea, et al.
Publicado: (2021)

The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms
por: Sacco, Monica, et al.
Publicado: (2022)

Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease
por: Abdelmaguid, Alyaa, et al.
Publicado: (2022)

A novel assay for studying the involvement of blood cells in whole blood thrombin generation
por: Wan, Jun, et al.
Publicado: (2020)

Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay
por: Wan, Jun, et al.
Publicado: (2020)

A hydrophobic patch (PLVIVG; 1481–1486) in the B‐domain of factor V‐short is crucial for its synergistic TFPIα‐cofactor activity with protein S and for the formation of the FXa‐inhibitory complex comprising FV‐short, TFPIα, and protein S
por: Dahlbäck, Björn, et al.
Publicado: (2022)

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies
por: Markusic, David M, et al.
Publicado: (2013)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

Thromboelastography‐guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis
por: Dias, João D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qap82ruqmkmaspq36lf8vvdso6